Arbutus Biopharma Corp Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-07-25: Study NCT06154278; Company role Collaborator; Phase Phase 2; Status Recruiting.
- 2024-07-11: Study NCT06277037; Company role Lead sponsor; Phase Observational; Status Recruiting.
- 2024-05-01: Study NCT06245291; Company role Lead sponsor; Phase Phase 2; Status Withdrawn.
- 2023-08-30: Study NCT05960240; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-07-25 | NCT06154278 Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B | Collaborator Lead: University of Maryland, Baltimore | Phase 2 | Recruiting | Chronic Hepatitis B | 10 | 2027-07-01 |
| 2024-07-11 | NCT06277037 Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) | Lead sponsor | Observational | Recruiting | Long Term Follow-up | 50 | 2029-10-30 |
| 2024-05-01 | NCT06245291 Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection | Lead sponsor | Phase 2 | Withdrawn | Hepatitis B, Chronic | 0 | 2024-08-01 |
| 2023-08-30 | NCT05960240 Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects. | Lead sponsor | Phase 1 | Completed | Chronic Hepatitis b | 128 | 2026-02-09 |
| 2021-10-29 | NCT04980482 Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection | Lead sponsor | Phase 2 | Completed Results posted | Chronic Hepatitis b | 43 | 2025-05-21 |
| 2021-06-25 | NCT04775797 Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection | Lead sponsor | Phase 1 | Terminated | Chronic Hepatitis | 110 | 2022-11-17 |
| 2021-05-07 | NCT04820686 A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection | Collaborator Lead: Assembly Biosciences | Phase 2 | Terminated Results posted | Chronic Hepatitis B | 65 | 2023-03-30 |
| 2015-12 | NCT02631096 Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy | Lead sponsor | Phase 2 | Completed | Hepatitis B, Chronic | 36 | 2018-05-18 |
| 2014-06 | NCT02191878 Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma | Lead sponsor | Phase 1, Phase 2 | Completed | Hepatocellular Carcinoma; Hepatoma; Liver Cancer, Adult; Liver Cell Carcinoma, Adult | 43 | 2016-07 |
| 2014-01 | NCT02041715 Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802 | Lead sponsor | Phase 1 | Terminated | Ebola Virus Infection | 21 | 2015-07 |
| 2012-01 | NCT01518881 Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion | Lead sponsor | Phase 1 | Terminated | Ebola Virus Infection | 24 | 2012-07 |
| 2010-12 | NCT01262235 A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | Lead sponsor | Phase 1, Phase 2 | Completed | Cancer; Neuroendocrine Tumors; NET; Adrenocortical Carcinoma; ACC | 68 | 2015-08 |
| 2009-06 | NCT00927459 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol | Lead sponsor | Phase 1 | Terminated | Hypercholesterolemia | 23 | 2010-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |